Atossa Genetics Inc. (ATOS) News
Filter ATOS News Items
ATOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATOS News Highlights
- ATOS's 30 day story count now stands at 3.
- Over the past 11 days, the trend for ATOS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRMA, ICCM and STAB are the most mentioned tickers in articles about ATOS.
Latest ATOS News From Around the Web
Below are the latest news stories about Atossa Therapeutics Inc that investors may wish to consider to help them evaluate ATOS as an investment opportunity.
IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losersIceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%. |
The Olympics Business Model: Why Multi-Year Media Deals MatterThe Olympic Games have been a revenue generating enterprise for the IOC from nearly their inception. WSJ’s Stu Woo unpacks the history of brand partnerships and the challenges sponsors are facing at the Beijing Games. Photo: Fabrizio Bensch/Reuters |
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: To Our Valued Stockholders: The last two years have changed the face of public health and uncovered t |
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary DiseaseSEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it is advancing to |
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in SwedenSEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast dens |
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut PasteurPhysician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus r |
Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug AdministrationInput Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant SettingSEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that it has completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to ob |
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”Atossa’s CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO will address a series of questions regarding Atossa’s research programs and future developmentsSEATTLE, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle |
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateSEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments. Key developments from Q3 2021 and to date include: Began to enroll participants in its clinical |